Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.46 |
| ▸ | RAB9A | P51151 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | AMY1A | P0DUB6 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | NPBWR1 | P48145 | 4/20 | 0.44 |
| ▸ | PTGES | O14684 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | METAP1 | P53582 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | GUSB | P08236 | 1/20 | 0.39 |
| ▸ | MET | P08581 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL986989 | 0.85 | ALDH1A1 (0.46) | NPC1RAB9AALDH1A1L3MBTL1AMY1A | |
| SCHEMBL986842 | 0.85 | NPBWR1 (0.62) | NPC1RAB9AALDH1A1L3MBTL1AMY1A | |
| SCHEMBL984422 | 0.82 | RAB9A (0.59) | NPC1RAB9AALDH1A1L3MBTL1MAPT | |
| SCHEMBL2973918 | 0.80 | NPBWR1 (0.44) | NPC1RAB9AALDH1A1L3MBTL1AMY1A | |
| SCHEMBL984215 | 0.80 | MAPT (0.49) | NPC1RAB9AALDH1A1MAPTMEN1 | |
| SCHEMBL3190704 | 0.80 | AMY1A (0.59) | NPC1RAB9AALDH1A1L3MBTL1PKM | |
| SCHEMBL986675 | 0.78 | NPC1 (0.51) | NPC1RAB9AALDH1A1L3MBTL1PKM | |
| SCHEMBL13607846 | 0.78 | PTGES (0.55) | NPC1RAB9AALDH1A1L3MBTL1PKM | |
| SCHEMBL5251968 | 0.78 | NPC1 (0.59) | NPC1RAB9AALDH1A1MAPTMEN1 | |
| SCHEMBL3190714 | 0.77 | AMY1A (0.73) | NPC1RAB9AALDH1A1L3MBTL1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10301280-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2019-05-28 | — | — | US | disclosed |
| EP-2935248-B1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2018-02-28 | — | — | EP | disclosed |
| US-20170349572-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2017-12-07 | — | — | US | disclosed |
| US-20170349572-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2017-12-07 | — | — | US | disclosed |
| US-20170349572-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2017-12-07 | — | — | US | disclosed |
| US-9676748-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-9676748-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-9676748-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2017-06-13 | — | — | US | disclosed |
| EP-2935248-A2 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | Plexxikon, Inc. (US) | 2015-10-28 | — | — | EP | disclosed |
| US-20140213554-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2014-07-31 | — | — | US | disclosed |
| US-20140213554-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2014-07-31 | — | — | US | disclosed |
| WO-2014100620-A2 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2014-06-26 | — | — | WO | disclosed |
| WO-2014100620-A2 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2014-06-26 | — | — | WO | disclosed |
| EP-2265609-B1 | IMDIZO [4. 5-B] PYRIDINE DERIVATIVES USED AS RAF INHIBITORS | ARRAY BIOPHARMA INC (US) | 2012-09-05 | — | — | EP | disclosed |
| US-20110003809-A1 | IMIDAZO [4,5-B] PYRIDINE DERIVATIVES USED AS RAF INHIBITORS | ARRAY BIOPHARMA INC. | 2011-01-06 | — | — | US | disclosed |
| EP-2265609-A1 | IMDIZO [4. 5-B] PYRIDINE DERIVATIVES USED AS RAF INHIBITORS | Array Biopharma, Inc. (US) | 2010-12-29 | — | — | EP | disclosed |
| WO-2009111277-A9 | IMIDAZO [4. 5-B] PYRIDINE DERIVATIVES USED AS RAF INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2009-12-30 | — | — | WO | disclosed |
| WO-2009111277-A1 | IMDIZO [4. 5-B] PYRIDINE DERIVATIVES USED AS RAF INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2009-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140213554-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | KIT, PRKCH, PRKACA | NPC1 2755/4885RAB9A 1022/4885ALDH1A1 2054/4885 |
| US-20110003809-A1 | IMIDAZO [4,5-B] PYRIDINE DERIVATIVES USED AS RAF INHIBITORS | BRAF, RAF1, ARAF | NPC1 3527/4885RAB9A 752/4885ALDH1A1 1091/4885 |
| US-10301280-B2 | Compounds and methods for kinase modulation, and indications therefor | KIT, PRKCH, PRKACA | NPC1 2755/4885RAB9A 1022/4885ALDH1A1 2054/4885 |
| US-20170349572-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | KIT, PRKCH, PRKACA | NPC1 2755/4885RAB9A 1022/4885ALDH1A1 2054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.